126 related articles for article (PubMed ID: 7882454)
1. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
Bates SE; Meadows B; Goldspiel BR; Denicoff A; Le TB; Tucker E; Steinberg SM; Elwood LJ
Cancer Chemother Pharmacol; 1995; 35(6):457-63. PubMed ID: 7882454
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
3. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
4. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
[TBL] [Abstract][Full Text] [Related]
6. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
7. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.
Murren JR; Durivage HJ; Buzaid AC; Reiss M; Flynn SD; Carter D; Hait WN
Cancer Chemother Pharmacol; 1996; 38(1):65-70. PubMed ID: 8603454
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
Spielmann M; Dorval T; Turpin F; Antoine E; Jouve M; Maylevin F; Lacombe D; Rouesse J; Pouillart P; Tursz T
J Clin Oncol; 1994 Sep; 12(9):1764-70. PubMed ID: 8083698
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer.
Zaman K; Durando X; Baurain JF; Humblet Y; Mazzeo F; Bostnavaron M; Meheust N; Monnoyer-Favrel S; Machiels JP; Bauer J
Breast Cancer Res Treat; 2011 Jun; 127(3):689-96. PubMed ID: 21442199
[TBL] [Abstract][Full Text] [Related]
10. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
11. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
14. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
15. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil.
Linn SC; van Kalken CK; van Tellingen O; van der Valk P; van Groeningen CJ; Kuiper CM; Pinedo HM; Giaccone G
J Clin Oncol; 1994 Apr; 12(4):812-9. PubMed ID: 7908691
[TBL] [Abstract][Full Text] [Related]
18. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
Berruti A; Sperone P; Bottini A; Gorzegno G; Lorusso V; Brunelli A; Botta M; Tampellini M; Donadio M; Mancarella S; De Lena M; Alquati P; Dogliotti L
J Clin Oncol; 2000 Oct; 18(19):3370-7. PubMed ID: 11013277
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
